<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100955">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079259</url>
  </required_header>
  <id_info>
    <org_study_id>Aquadex</org_study_id>
    <nct_id>NCT02079259</nct_id>
  </id_info>
  <brief_title>CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure</brief_title>
  <acronym>Aquadex</acronym>
  <official_title>CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure - A Pilot Study to Optimize Individualized Volume Depletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of patients with acute congestion on chronic heart failure is increasing.
      Ultrafiltration has recently been proposed as an alternative approach for the stabilization
      of volume balance, especially in patients with imminent diuretic resistance.

      There is increasing evidence that ultrafiltration may relief cardiac congestion with lesser
      effects on blood pressure and activation of renin angiotensin system, respectively .
      However, recent studies revealed conflicting results: demonstration the superiority of
      ultrafiltration in comparison to diuretic treatment, and a lack of evidence of benefit, as
      well as an excess of adverse events with ultrafiltration.

      Aquapheresis with adapted ultrafiltration rate guided by central venous pressure is safer
      than aquaphesis with a constant ultrafiltration with comparable effectiveness
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes in central venous pressure</measure>
    <time_frame>Changes from Baseline to 48 h after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>amount of net fluid loss</measure>
    <time_frame>48 h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of dyspnea using a visual analog scale</measure>
    <time_frame>Changes from Baseline to 48 h after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart function</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>right/left heart function measured by Echocardiography and BNP (Brain Natriuretic Peptide)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>Changes from Baseline to 48 h after intervention</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>GFR, Cystatin C, HCO3-, NT-proBNP, CK, Troponin, Hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until impaired plasma refill rate</measure>
    <time_frame>48 h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Changes from Baseline to 48 h after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>Changes from Baseline to 48 h after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine level</measure>
    <time_frame>48 h</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrafiltration</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic heart failure listed for LVAD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic heart failure scheduled for LVAD

          -  Indication for CVVH/Aquapheresis

        Exclusion Criteria:

          -  Renal Disease (GFR &lt;20 ml / min)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Westenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malte Kelm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf Westenfeld, MD</last_name>
    <email>ralf.westenfeld@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabea Wagstaff, B.Sc., M.A.</last_name>
    <email>rabea.wagstaff@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefanie Keymel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralf Westenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-duesseldorf.de/Kardiologie</url>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
